¥á1 Çׯ®¸³½Å °áÇÌÁõ Ä¡·á ½ÃÀå º¸°í¼­ : Ä¡·á À¯Çü, Åõ¿© °æ·Î, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)
Alpha 1 Antitrypsin Deficiency Treatment Market Report by Treatment Type, Route of Administration, End User, and Region 2025-2033
»óǰÄÚµå : 1800975
¸®¼­Ä¡»ç : IMARC
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 123 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,221,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ® µîÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,628,000
PDF & Excel (5 User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ Copy&Paste°¡ ºÒ°¡´ÉÇÕ´Ï´Ù. Àμâ´Â 5ºÎ±îÁö °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,036,000
PDF & Excel (Corporate License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ Copy&Paste°¡ ºÒ°¡´ÉÇÕ´Ï´Ù. Àμâ´Â 5ºÎ±îÁö °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ¥á1 Çׯ®¸³½Å °áÇÌÁõ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2024³â 22¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 42¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 7.22%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

¥á-1 Çׯ®¸³½Å(AAT) °áÇÌÁõÀº ü³»¿¡¼­ AAT ´Ü¹éÁúÀÌ ÃæºÐÈ÷ »ý¼ºµÇÁö ¾Ê´Â À¯ÀüÀû ÁúȯÀ» ¸»ÇÕ´Ï´Ù. AAT ´Ü¹éÁúÀº Æó¿Í °£À» ´Ù¸¥ ´Ü¹éÁúÀÇ À¯ÇØÇÑ ¿µÇâÀ¸·ÎºÎÅÍ º¸È£ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ÁßÁõ AAT °áÇÌ È¯ÀÚ´Â °£°æÈ­, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), Æó±âÁ¾ ÁúȯÀÌ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. À¯ÀüÀÚ °Ë»ç³ª Ç÷¾× °Ë»ç·Î Áø´ÜÇÒ ¼ö ÀÖ½À´Ï´Ù. Ä¡·á¹ýÀ¸·Î´Â ±â°üÁö È®ÀåÁ¦, ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀÌµå µîÀÇ ¾à¹°À» Á¤¸ÆÁÖ»çÇϰųª ÈíÀÔÇÏ´Â º¸°­¿ä¹ý, Æó ÀçȰġ·á, »ê¼Ò¿ä¹ý µîÀÌ ÀÖ½À´Ï´Ù.

È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, °­È­ ¿ä¹ýÀÌ ³Î¸® äÅõǰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÌ Ä¡·á¹ýÀº °Ç°­ÇÑ ±âÁõÀÚÀÇ Ç÷Àå¿¡¼­ AAT ´Ü¹éÁúÀ» ÃßÃâÇÏ¿© ȯÀÚÀÇ È£Èí±â ³» AAT ³óµµ¸¦ ³ôÀÔ´Ï´Ù. ÀÌ¿¡ µû¶ó ÀÌ Ä¡·á¹ýÀº Æó±âÁ¾ÀÇ ÁøÇàÀ» ´ÊÃß°í ¾ÇÈ­ ºóµµ¸¦ ÃÖ¼ÒÈ­Çϸç ȸº¹ ¼Óµµ¸¦ Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ, Áø´Ü¹ýÀÇ ´Ù¾çÇÑ ±â¼úÀû Áøº¸¿Í AAT »ý»ê ¹× Á¤Á¦ °úÁ¤ÀÇ Çõ½ÅÀû ÇÁ·Î¼¼½º °³¹ßµµ ´Ù¸¥ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. AAT´Â ǰÁúÀÌ Çâ»óµÇ°í ¹ÙÀÌ·¯½º³ª ¹ÚÅ׸®¾Æ µîÀÇ ¿À¿°¹°ÁúÀÌ Æ÷ÇԵǾî ÀÖÁö ¾Ê½À´Ï´Ù. ±âŸ ¿äÀÎÀ¸·Î´Â ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿, ÀÇ·á ÀÎÇÁ¶ó °³¼± µîÀÌ ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ ¥á1 Çׯ®¸³½Å °áÇÌÁõ Ä¡·á ½ÃÀå

Á¦6Àå ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°

Á¦7Àå ½ÃÀå ºÐ¼® : Åõ¿© °æ·Îº°

Á¦8Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦10Àå SWOT ºÐ¼®

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå PorterÀÇ Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global alpha 1 antitrypsin deficiency treatment market size reached USD 2.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.2 Billion by 2033, exhibiting a growth rate (CAGR) of 7.22% during 2025-2033.

Alpha-1 antitrypsin (AAT) deficiency refers to a genetic disorder due to which the body does not produce sufficient AAT protein. AAT protein is essential for protecting the lungs and liver from the adverse effects of other proteins in the body. Patients with severe AAT deficiency may develop liver cirrhosis, chronic obstructive pulmonary diseases (COPD) and emphysema diseases. It can be diagnosed through a genetic or a blood test. Some of the treatment methods include augmentation therapy, pulmonary rehabilitation and oxygen therapy that use medicines, such as bronchodilators and corticosteroids, which can be injected intravenously or inhaled.

The increasing prevalence of respiratory disorders is one of the key factors driving the growth of the market. Furthermore, widespread adoption of augmentation therapy is providing a thrust to the market growth. This therapy involves extracting AAT protein from a healthy donor's blood plasma for increasing AAT levels in the respiratory tract of patients. In line with this, this treatment also delays the progression of emphysema, minimizes the frequency of exacerbations and improves recovery speed, which, in turn, is contributing to its increasing preference among both the patients and healthcare providers. Additionally, various technological advancements in the diagnostic methods and the development of innovative processes for the production and purification of AAT are acting as other growth-inducing factors. They have improved quality and are free from contaminants, such as viruses and bacteria. Other factors, including extensive research and development (R&D) activities, along with improvements in medical infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Treatment Type:

Breakup by Route of Administration:

Breakup by End User:

Breakup by Region:

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AstraZeneca PLC, C.H. Boehringer Sohn AG & Ko. KG, CSL Limited, GlaxoSmithKline Plc, Grifols S.A., Kamada Ltd., LFB Biomedicaments S.A., Pfizer Inc., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Alpha 1 Antitrypsin Deficiency Treatment Market

6 Market Breakup by Treatment Type

7 Market Breakup by Route of Administration

8 Market Breakup by End User

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â